Piperazine derivatives as cav2.2 calcium channel blockers

Convergence Pharmaceutical Ltd 2012. Piperazine derivatives as cav2.2 calcium channel blockers. WO2012098400A1. [Patent].

Full text not available from this repository.

Abstract

The invention relates to novel piperazine compounds; to processes for their preparation; to pharmaceutical composi tions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca 2.2 calcium channels is beneficial, i.e. in particular to treat pain.

Item Type:	Patent
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Last Modified:	24 Oct 2022 08:43
URI:	https://orca.cardiff.ac.uk/id/eprint/118529

Actions (repository staff only)

Edit Item